The discordance between AS, particularly for LA-HR+/HER2- BC, with prognostic stage presents a clinical challenge in recommending personalized treatments especially since prior studies demonstrated greater nodal involvement is a key determinant in prognosis and is significantly associated with an increased risk for disease recurrence [35,36]. Here, ERBB2 is linked to breast cancer.